SCM
PTCT icon

Stevens Capital Management’s PTC Therapeutics PTCT Stock Holding History

Stevens Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-5,519
Closed -$266K – 1173
2015
Q2 		$266K Buy
+5,519
New +$322K 0.01% 788

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Stevens Capital Management's PTCT Position: Q3 2015 in Review

Stevens Capital Management sold out of PTC Therapeutics (PTCT) in Q3 2015, closing a stake of 5,519 shares — an estimated $266K sold.

Stevens Capital Management first reported a position in PTCT in Q2 2015 and held it in 1 quarter. The position peaked at $266K in Q2 2015. 157 funds tracked by Wall St. Rank hold PTCT as of Q3 2015.

  • Stevens Capital Management reported no remaining PTC Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Stevens Capital Management sold 5,519 PTC Therapeutics shares in Q3 2015, an estimated $266K.
  • Stevens Capital Management first reported a position in PTC Therapeutics in Q2 2015 and held it in 1 quarter.
  • Stevens Capital Management's PTC Therapeutics position peaked at $266K in Q2 2015.
  • 157 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2015.

Based on Stevens Capital Management's 13F filing for Q3 2015, filed 10 Nov 2015.